Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Soft antibacterial agents.

T Thorsteinsson1, T Loftsson, M Masson

  • 1Faculty of Pharmacy, University of Iceland, Hofsvallagata 53, 107 Reykjavik, Iceland. thorstlo@hi.is

Current Medicinal Chemistry
|April 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking emotional valence and anxiety in a mouse insula-amygdala circuit.

Nature communications·2023
Same author

Screening and treatment of Post-Selective Serotonin Reuptake Inhibitors sexual dysfunctions.

L'Encephale·2022
Same author

Creating a new chapter in the DSM for late-onset depressive disorders.

L'Encephale·2022
Same author

Barriers and opportunities for the continuous training of healthcare professionals in the post-Covid era.

L'Encephale·2022
Same author

The neuroinflammatory pathways of post-SARS-CoV-2 psychiatric disorders.

L'Encephale·2021
Same author

Psychotropics and COVID-19: An analysis of safety and prophylaxis.

L'Encephale·2021
Same journal

Screening of Medicinal and Edible Homology Substances for Diabetic Kidney Disease Based on GraphBAN.

Current medicinal chemistry·2026
Same journal

Berberine as an Antimicrobial Agent and Gut Microbiota Modulator: Mechanisms and Therapeutic Potential.

Current medicinal chemistry·2026
Same journal

Research Progress of Grapefruit-derived Extracellular Vesicles in Anti-tumor Treatment.

Current medicinal chemistry·2026
Same journal

Corrigendum to: Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke.

Current medicinal chemistry·2026
Same journal

Ferroptosis and Its Crosstalk with Other Cell Death Modes in Ischemic Stroke.

Current medicinal chemistry·2026
Same journal

Integrative Analysis Reveals BPTF, COL1A1, and COL4A2 as Fibroblast-Related Biomarkers Associated with Immune Infiltration in Ovarian Cancer.

Current medicinal chemistry·2026
See all related articles

This study introduces soft drug analogs as potentially less toxic antibacterial agents. While effective in vitro, their in vivo application faces challenges due to chemical instability.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Antimicrobial Agents

Background:

  • Hard drugs are biologically active and non-metabolizable, posing toxicity and resistance issues.
  • Quaternary ammonium compounds (e.g., benzalkonium chloride) are hard antibacterials with limited human/environmental use due to stability and toxicity.
  • Bacterial resistance is a growing concern with persistent antimicrobial agents.

Purpose of the Study:

  • To explore soft drug analogs as alternatives to hard antibacterial agents.
  • To evaluate the potential of soft drugs to overcome the limitations of hard drugs.
  • To investigate the balance between therapeutic efficacy and in vivo stability for novel antibacterials.

Main Methods:

  • Definition and characterization of hard vs. soft drugs based on metabolism.

Related Experiment Videos

  • Review of quaternary ammonium compounds as examples of hard drugs.
  • Assessment of in vitro antibacterial activity and in vivo stability considerations for soft analogs.

    • Main Results:

    • Soft drug analogs offer reduced toxicity compared to hard antibacterial agents.
    • In vitro studies indicate antibacterial activity for soft analogs.
    • Chemical instability in vivo may limit the therapeutic efficacy of soft drug analogs.

    Conclusions:

    • Soft drug design presents a promising avenue for developing safer antibacterials.
    • Further research is needed to address the in vivo stability challenges of soft drug analogs.
    • Balancing efficacy and controlled degradation is key for next-generation antimicrobial therapies.